Biohaven completes enrollment in phase 2 obesity study

March 19, 2026 7:30 AM

Biohaven Ltd. (NYSE: BHVN) announced the completion of enrollment in its Phase 2 study evaluating taldefgrobep alfa for obesity treatment ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found